Relative Risk Factor of Axillary Lymph Node Metastasis in Early Breast Carcinoma, Samutsakhon Hospital
Keywords:
breast cancer, axillary management, axillary lymph node metastasisAbstract
The objective of this research was to study the incidence of lymph node metastasis and the associated factors in early-stage breast cancer in Samutsakhon Hospital. A retrospective descriptive study included 303 patients who underwent mastectomy with lymph node dissection in the surgical department of Samutsakhon Hospital from 1 January 2016 to 31 December 2021.The patient epidemiology, radiologic data, type of procedures, and pathology report data were collected from medical records to evaluate the incidence of lymph node metastasis in each patient group and to analyze the associated factors utilizing Pearson’s Chi-square test and Fisher’s exact test. There were patients who underwent axillary lymph node dissection (ALND) 74.2% and sentinel lymph node biopsy (SLNB) 25.8%. Pathological node-negative (pN0) incidence was 51.2% of all patients and 77.1% of SLNB patients. The incidence of clinical node-negative (cN0) patients who had pathological nodenegative (pN0) was 63.1%. The most common location was the upper-outer quadrant, and the size was mainly 2-5 cm. The increased size of the mass, the round-shaped lymph node, and lymphovascular invasion were statistically significantly associated with axillary lymph node metastasis. In conclusion, Physical radiological examination and preoperative pathological report are essential to evaluate the preoperative lymph node status in order to consider the appropriate type of axillary management.
References
National Cancer Center Institute Department of Medical Services Minister of Public Heath Thailand. Hospital-Base Cancer Registry Annual Report 2016. Bangkok: Information Technology Division National Cancer Institute; 2018.
Auchincloss H. Significant of Location and Number of Axillary Metastases in Carcinoma of The Breast. Ann Surg 1963;158:37-46.
Madden JL, Kandalaft S. Bourque RA. Modified radical mastectomy. Ann Surg. 1972;175:624-34.
Fisher B, Slack N, Katrych D, Wolmark N. Ten year follow-up results of patients with carcinoma of the breast in a co-operative clinical trial evaluating surgical adjuvant chemotherapy. Surg Gynecol Obst. 1975;140:528-34.
Roses DF, Brooks AD, Harris MN, Shapiro RL, Mitnick J. Complications of level I and II axillary dissection in the treatment of carcinoma of the breast. Ann Surg. 1999;230:194-201.
Warmuth MA, Bowen G, Prosnitz LR, Chu L, Broadwater G, Peterson B, Leight G, et al. Complications of axillary lymph node dissection for carcinoma of the breast: a report based on a patient survey. Cancer: Inter J Amer Cancer Society. 1998;83:1362-8.
Veronesi U, Paganelli G, Viale G, Luini A, Zurrida S, Galimberti V, et al. Sentinel-lymph-node biopsy as a staging procedure in breast cancer: update of a randomised controlled study. Lancet Oncol. 2006;7:983-90.
Krag DN, Anderson SJ, Julian TB, Brown AM, Harlow SP, Ashikaga T, et al. Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial. Lancet Oncol. 2007;8:881-8.
Gill PG. Sentinel lymph node biopsy versus axillary clearance in operable breast cancer: The RACS SNAC trial, a multicenter randomized trial of the Royal Australian College of Surgeons (RACS) Section of Breast Surgery, in collaboration with the National Health and Medical Research Council Clinical Trials Center. Ann Surg Oncol. 2004;11:216S-21S.
Mansel RE, Fallowfield L, Kissin M, Goyal A, Newcombe RG, Dixon JM, et al. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial. J Natl Cancer Inst. 2006;98:599-609.
Purushotham AD, Upponi S, Klevesath MB, Bobrow L, Millar K, Myles JP, et al. Morbidity after sentinel lymph node biopsy in primary breast cancer: results from a randomized controlled trial. J Clin Oncol. 2005;23:4312-21.
Giuliano AE, Hunt KK, Ballman KV, Beitsch PD, Whitworth PW, Blumencranz PW, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA. 2011;305:569-75.
NCCN Clinical Practice Guidelines in Oncology. Breast Cancer [internet] v2.2024. [cited 2024 May 13. Available from: www.nccn.org/professionals/physician_gls/pdf/breast.pdf
Yoshihara E, Smeets A, Laenen A, Reynders A, Soens J, Van Ongeval C, et al. Predictors of axillary lymph node metastases in early breast cancer and their applicability in clinical practice. Breast. 2013;22:357-61.
Guo Q, Dong Z, Zhang L, Ning C, Li Z, Wang D, et al. Ultrasound features of breast cancer for predicting axillary lymph node metastasis. J Ultrasound Med. 2018;37:1345-53.
Zahoor S, Haji A, Battoo A, Qurieshi M, Mir W, Shah M. Sentinel lymph node biopsy in breast cancer: a clinical review and update. J breast cancer. 2017;20:217-27.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Articles in this journal are copyrighted by the x may be read and used for academic purposes, such as teaching, research, or citation, with proper credit given to the author and the journal.use or modification of the articles is prohibited without permission.
statements expressed in the articles are solely the opinions of the authors.
authors are fully responsible for the content and accuracy of their articles.
other reuse or republication requires permission from the journal."
